Dual REctcal Angiogenesis or MEK Inhibition radioTHERAPY Trial
Status:
Terminated
Trial end date:
2016-11-04
Target enrollment:
Participant gender:
Summary
To determine the maximum tolerated dose (MTD) of AZD6244 or AZD2171 when combined with
pre-operative capecitabine and radiotherapy in patients with locally advanced rectal cancer.